Filgotinib

Filgotinib
Clinical data
Trade names	Jyseleca
Other names	GLPG0634, GS-6034
Routes of; administration	By mouth
Drug class	Janus kinase inhibitor
ATC code	L04AF04 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Elimination half-life	6 hours
Identifiers
	IUPAC name N-[5-[4-[(1,1-Dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide;
CAS Number	1206161-97-8 ;
PubChem CID	49831257;
IUPHAR/BPS	7913;
DrugBank	DB14845 ;
ChemSpider	28189566 ;
UNII	3XVL385Q0M;
KEGG	D10871 ; as salt: D11106 ;
ChEMBL	ChEMBL3301607 ;
PDB ligand	2HB (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID80152935 ;
Chemical and physical data
Formula	C21H23N5O3S
Molar mass	425.51 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1nc2cccc(-c3ccc(CN4CCS(=O)(=O)CC4)cc3)n2n1)C1CC1;
	InChI InChI=1S/C21H23N5O3S/c27-20(17-8-9-17)23-21-22-19-3-1-2-18(26(19)24-21)16-6-4-15(5-7-16)14-25-10-12-30(28,29)13-11-25/h1-7,17H,8-14H2,(H,23,24,27) ; Key:RIJLVEAXPNLDTC-UHFFFAOYSA-N ;
	(what is this?) (verify)

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV.

The most common side effects include nausea (feeling sick), upper respiratory tract infection (nose and throat infection), urinary tract infection and dizziness.

Filgotinib was approved for medical use in both the European Union and Japan in September 2020.